ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

ClinicalTrials.gov ID: NCT04711252

Public ClinicalTrials.gov record NCT04711252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Study identification

NCT ID
NCT04711252
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,370 participants

Conditions and interventions

Interventions

  • AZD9833 Drug
  • AZD9833 placebo Drug
  • Anastrozole Drug
  • Anastrozole placebo Drug
  • Luteinizing hormone-releasing hormone (LHRH) agonist Drug
  • Palbociclib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 27, 2021
Primary completion
Aug 23, 2026
Completion
Jan 31, 2029
Last update posted
Oct 13, 2025

2021 – 2029

United States locations

U.S. sites
30
U.S. states
21
U.S. cities
28
Facility City State ZIP Site status
Research Site Mobile Alabama 36604
Research Site Springdale Arkansas 72762
Research Site Harbor City California 90710
Research Site Solvang California 93463
Research Site Lone Tree Colorado 80124
Research Site Fort Myers Florida 33901-8101
Research Site Jacksonville Florida 32256
Research Site West Palm Beach Florida 33401
Research Site Indianapolis Indiana 46256
Research Site Baton Rouge Louisiana 70809
Research Site Silver Spring Maryland 20904
Research Site Boston Massachusetts 02114
Research Site Detroit Michigan 48202
Research Site Hattiesburg Mississippi 39401
Research Site Omaha Nebraska 68130
Research Site Cincinnati Ohio 45219
Research Site Cincinnati Ohio 45267
Research Site Portland Oregon 97239
Research Site West Columbia South Carolina 29169
Research Site Sioux Falls South Dakota 57105
Research Site Chattanooga Tennessee 37404
Research Site Nashville Tennessee 37203
Research Site Austin Texas 78731
Research Site Houston Texas 77030
Research Site Houston Texas 77090
Research Site Tyler Texas 75702
Research Site Fairfax Virginia 22031
Research Site Kennewick Washington 99336
Research Site Renton Washington 98055
Research Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 233 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04711252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 13, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04711252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →